首页> 外文期刊>Cytokine >IL-18/IL-1/IL-17A axis: A novel therapeutic target for neonatal sepsis?
【24h】

IL-18/IL-1/IL-17A axis: A novel therapeutic target for neonatal sepsis?

机译:IL-18 / IL-1 / IL-17A轴:新生儿败血症的新型治疗靶点?

获取原文
获取原文并翻译 | 示例
           

摘要

Healthy and septic human neonates have elevated serum IL-18 levels compared with adults. Using a murine neonatal model of intraabdominal sepsis with systemic (intraperitoneal) IL-18 complementation, Wynn et al. report that IL-18 potentiated mortality in both neonatal sepsis and endotoxemia through the induction of IL-17A, and depended on IL-1 receptor I signaling (but not IL-1 beta). They propose that targeting this IL-18/IL-1/IL-17A axis may improve outcomes for human neonates with sepsis. However, given the important roles of Th17 responses and IL-18 in host defenses, some caution is in order during a potentially microbe-induced septic process in neonates. The important differences in neonatal and adult responses to sepsis highlighted in this paper emphasize the need for further study of the immune responses of neonates. (C) 2016 Elsevier Ltd. All rights reserved.
机译:与成年人相比,健康和脓毒症的人类新生儿血清IL-18水平升高。 Wynn等人使用具有系统性(腹膜内)IL-18互补作用的腹腔内脓毒症小鼠新生模型。报告指出IL-18通过诱导IL-17A增强了败血症和内毒素血症的死亡率,并且依赖于IL-1受体I信号传导(但不依赖IL-1β)。他们建议针对此IL-18 / IL-1 / IL-17A轴可改善败血症人类新生儿的预后。然而,考虑到Th17应答和IL-18在宿主防御中的重要作用,在新生儿中潜在的微生物诱导的败血症过程中应谨慎行事。本文强调的新生儿和成人对败血症的重要区别强调了对新生儿免疫反应的进一步研究的必要性。 (C)2016 Elsevier Ltd.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号